FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

17 results

bosulif
(Bosutinib)
U.S. Pharmaceuticals
Usage: BOSULIF is indicated for treating adults and pediatric patients (1 year and older) with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), as well as adults with accelerated or blast phase Ph+ CML who are resistant or intolerant to prior therapies.
caverject impulse
(Alprostadil)
U.S. Pharmaceuticals
Usage: CAVERJECT IMPULSE is indicated for treating erectile dysfunction and as an adjunct to other diagnostic tests for diagnosing erectile dysfunction.
cibinqo
(abrocitinib)
U.S. Pharmaceuticals
Usage: CIBINQO is indicated for treating refractory, moderate-to-severe atopic dermatitis in adults and patients aged 12 and older, when the condition is not adequately managed by other systemic therapies or when those treatments are unsuitable. Co-use with other JAK inhibitors or biologics is not recommended.
duavee
(conjugated estrogens/bazedoxifene)
U.S. Pharmaceuticals
Usage: DUAVEE is indicated for women with a uterus to treat moderate to severe vasomotor symptoms related to menopause and to prevent postmenopausal osteoporosis. It should be used for the shortest duration necessary, with periodic re-evaluation of treatment needs.
elrexfio - elranatamab - bcmm injection, solution
(Elranatamab-Bcmm)
U.S. Pharmaceuticals
ibrance
(palbociclib)
U.S. Pharmaceuticals
Usage: IBRANCE is indicated for adult patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, used in combination with an aromatase inhibitor as initial therapy or fulvestrant after disease progression following endocrine therapy.
ibrance
(palbociclib)
U.S. Pharmaceuticals
Usage: IBRANCE is indicated for treating adult patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, either in combination with an aromatase inhibitor as initial endocrine therapy or with fulvestrant for those with disease progression after endocrine therapy.
inlyta
(axitinib)
U.S. Pharmaceuticals
Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for advanced RCC following the failure of one prior systemic therapy.
litfulo
(ritlecitinib)
U.S. Pharmaceuticals
Usage: LITFULO is indicated for treating severe alopecia areata in adults and adolescents aged 12 and older. It should not be used with other JAK inhibitors, biologic immunomodulators, cyclosporine, or potent immunosuppressants.
lorbrena - lorlatinib tablet, film coated
(Lorlatinib)
U.S. Pharmaceuticals

U.S. Pharmaceuticals drugs

bosulif

caverject impulse

cibinqo

duavee

elrexfio - elranatamab - bcmm injection, solution

ibrance

ibrance

inlyta

litfulo

lorbrena - lorlatinib tablet, film coated